Imagine a high-tech filter that can spot tiny chemical 'tags' on your DNA that signal cancer long before symptoms appear. This project created a specialized chip that reads these tags from a simple blood draw. It's like a barcode scanner for blood diseases, making early detection much cheaper and faster.
Current screening for blood cancers is often too expensive or lacks the sensitivity to detect diseases early. This leads to late-stage diagnoses for the 10% of cancer patients with hematological malignancies.
A custom microarray called HemaChip, validated reagents for fluorescent labeling of DNA, and a machine-learning software pipeline for data analysis.
If you are a diagnostics company dealing with high costs of liquid biopsy — this project developed the HemaChip and validated reagents that provide superior sensitivity at low-cost for screening.
If you are a biotech firm dealing with the complexity of DNA methylation analysis — this project developed a machine-learning-based analytical pipeline and direct fluorescent labeling for 5mC and 5hmC marks.
If you are a lab network dealing with low screening rates for hematological malignancies — this project developed an end-to-end solution including software and chips to implement large-scale screening in real-life clinical settings.
Based on available project data, the SANGUINE test is designed to provide superior sensitivity at low-cost, making it specifically ideal for large-scale screening purposes.
Yes, the project aims to provide HemaChips, validated reagents, and data analysis software specifically for large-scale screening and early-stage commercialization.
Based on available project data, the project is developing custom-designed microarrays and software, but specific patent or licensing terms are not listed.
The team is using a machine-learning pipeline and has analyzed 435 genomic DNA and 355 cell-free DNA samples from 9 different types of malignancies.
The project period runs from 2023-01-01 to 2026-12-31, suggesting the final commercial-ready components will be available by the end of 2026.
The consortium is well-balanced for commercialization, featuring 11 partners across 7 countries. With an industry ratio of 27% (including 4 SMEs), there is a strong bridge between the academic research led by Tel Aviv University and the market. The mix of 3 universities, 3 research institutes, and 3 industry partners ensures that the HemaChip moves from lab discovery to a validated product.
Contact Tel Aviv University regarding the HemaChip commercialization
Contact us to explore licensing opportunities for the HemaChip and its ML pipeline.
